Author:

European stocks climbed on Wednesday as investors assessed positive results from initial trials of an experimental coronavirus vaccine produced by biotechnology firm Moderna (MRNA). The potential vaccine, developed by researchers at the US National Institute of Allergy and Infectious Diseases, provoked a promising immune response and appeared safe in 45 healthy volunteers in an early-stage study. The pan-European STOXX 600 index (^STOXX) rose by around 1.2%, while London’s FTSE 100 (^FTSE) climbed by almost 1%. Germany’s DAX (^GDAXI) was up by around 1.2%, while France’s CAC 40 (^FCHI) climbed by almost 1.6%. The data from the Moderna trial built on earlier promising, but incomplete, results the company had released in May. A late-stage trial of the vaccine candidate is set to begin on 27...

Within 12 hours of getting the second dose of an experimental COVID-19 vaccine being developed by Moderna Inc., Ian Haydon began to feel chills. Then came nausea, headaches, muscle pain and delirium. He took his temperature: 103.2 degrees. The 29-year-old Seattle resident, one of 45 participants in the company’s Phase 1 clinical trial, knew his body was trying to mount a defense against the vaccine. If it worked, his immune system would be primed to fight an actual coronavirus infection. An aspiring marathon runner without any health issues, Haydon could not remember ever feeling this sick. His girlfriend took him to urgent care. Later that night, he fainted in their apartment. With fluids and rest, the symptoms faded. A day and half after getting the shot, he felt fine. Similar side ...

The first COVID-19 vaccine tested in the U.S. revved up people’s immune systems just the way scientists had hoped, researchers reported Tuesday -- as the shots are poised to begin key final testing. “No matter how you slice this, this is good news,” Dr. Anthony Fauci, the U.S. government’s top infectious disease expert, told The Associated Press. The experimental vaccine, developed by Fauci’s colleagues at the National Institutes of Health and Moderna Inc., will start its most important step around July 27: A 30,000-person study to prove if the shots really are strong enough to protect against the coronavirus. But Tuesday, researchers reported anxiously awaited findings from the first 45 volunteers who rolled up their sleeves back in March. Sure enough, the vaccine provided a hoped-for ...